incidence
The crude incidence of ovarian cancer in the European Union is 18, the mortality is 12/100 000 women/year. The median age at diagnosis is 63 years. The incidence increases with age and peaks in the eighth decade. Between the ages of 70 and 74 years the age-specific incidence is 57/100 000 women/year.

diagnosis
The definitive diagnosis of epithelial ovarian cancer requires a surgical specimen. Pathological diagnosis should be made according to the World Health Organization classification. Established subtypes are: serous, mucinous, endometrioid, clear cell, Brenner, mixed and undifferentiated carcinomas.

staging and risk assessment
Surgical staging requires a median laparotomy with a thorough examination of the abdominal cavity according to Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) classification guidelines. If disease appears confined to the ovary, biopsy of the diaphragmatic peritoneum, paracolic gutters, pelvic peritoneum and an infracolic omentectomy, and sampling or dissection of para-aortic and pelvic nodes are required in addition to peritoneal washings.

Surgery should be performed by an appropriately trained gynaecologic oncologist with experience in the management of ovarian cancer [III, B].

Staging is described using the FIGO and American Joint Committee on Cancer (AJCC) classification and FIGO as in the table below.

Established favorable prognostic factors besides surgical stage are: small tumor volume (before and after surgery), younger age, good performance status, cell type other than clear cell, well-differentiated tumor and absence of ascites. Low grade, absence of dense adhesions, minimal ascites, subgroups a/b versus c and cell type other than clear cell are considered good prognostic factors for patients with stage I disease.

Before surgery and/or chemotherapy, patients should have an abdomino-pelvic CT scan, chest X-ray, serum CA125, complete blood count and differential, and biochemistry for renal and hepatic function.

treatment plan
The selection of the type of surgery and postoperative chemotherapy depends upon the stage and other clinicopathological prognostic factors.

early stage disease, FIGO I and IIa
Surgery should involve total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, random peritoneal biopsies including the paracolic gutters and at least pelvic/para-aortic lymph node sampling performed as described above. In younger patients wanting to conserve fertility with localized, unilateral tumors (stage I) and favorable histology, unilateral salpingo-oophorectomy may not be associated with a high risk of recurrence. Wedge biopsy of the contralateral ovary should be performed, if the contralateral ovary is not normal on inspection. FIGO stage I tumors with dense adhesions to other pelvic structures should be ‘upstaged’ and treated as FIGO II tumors, as the relapse rate appears to be similar.

FIGO stage Ia/b, welldifferentiated, non-clear cell histology: surgery alone is adequate [I, A]. FIGO stage Ia/b poorly differentiated, densely adherent, clear cell histology and all grades FIGO stage Ic and IIa: optimal surgery and staging should be performed, and adjuvant chemotherapy considered [I, A].

Consider three cycles of carboplatin [area under the curve (AUC) 5–7 mg/ml/min] + paclitaxel 175 mg/m²/3 h for early stage ovarian cancer if combination therapy is to be used [II, A]. Otherwise, six cycles of carboplatin ± paclitaxel would seem appropriate.
advanced disease; FIGO stage IIb–IIic
Surgery should include total abdominal hysterectomy and bilateral salpingo-oophorectomy with omentectomy, with staging biopsies performed as described. Upfront maximal surgical effort at cytoreduction with the goal of no residual disease should be undertaken.

The recommended standard chemotherapy for advanced ovarian carcinoma, stages IIb–IIic is carboplatin AUC 5–7 mg/ml/min ± paclitaxel 175 mg/m²/3 h every 3 weeks for six cycles.

If initial maximal cytoreduction was not performed, interval debulking surgery should be considered in patients responding to chemotherapy, or showing stable disease [II, B]. Interval debulking surgery should ideally be performed after three cycles of chemotherapy, followed by three further cycles of chemotherapy.

There is no evidence for a survival benefit of ‘second-look’ surgery following completion of chemotherapy in patients whose disease appears to be in complete remission. Such procedures should only be undertaken as part of a clinical trial. Likewise, the value of secondary tumor reduction at the time of second-look laparotomy is not clear.

Intraperitoneal chemotherapy should be considered an option for selected patients in centers where the expertise exists.

Neoadjuvant chemotherapy for patients considered initially not optimally resectable for either tumor or patient-related factors is a viable alternative strategy; however, available data suggest that the survival outcome may be inferior to successful primary surgery followed by chemotherapy.

advanced disease; FIGO stage IV
Patients with stage IV disease may obtain a survival advantage from being maximally surgically cytoreduced at initial laparotomy [III, B], although randomized trials have not addressed this question.

Young patients with good performance status, pleural effusion as the only site of disease outside the abdominal cavity, small volume metastases and no major organ dysfunction should be considered for surgery as outlined above.

If surgery is not planned, the diagnosis should be confirmed by biopsy and chemotherapy administered as recommended above for FIGO stage IIb–IIic disease.

response evaluation
CA125 levels during chemotherapy can accurately correlate with tumor response and with survival [III, A]. Serum CA125 should be measured at regular intervals during chemotherapy (e.g. before each cycle).

For patients with abnormal CT scan at baseline, this should be repeated after cycle 6 unless there is evidence (e.g. CA125 levels not falling) of non-responding disease; in this case an earlier CT scan would be indicated. Patients with normal CT scans at baseline do not need further CT scans, provided there is no clinical or biochemical indication of disease progression. An interim CT scan after three cycles of chemotherapy should be considered for a patient who is negative for serum CA125, or for whom interval debulking surgery is being considered.

Current data do not support a recommendation of maintenance/consolidation treatment beyond six cycles; however, the data for 12 months of paclitaxel maintenance should be discussed with patients with respect to the potential improvement observed in PFS [II, C], especially in patients with low concentrations of CA125 [III, B]. Patients with a partial response (or elevated CA125) after six cycles of chemotherapy but continuing evidence of response by CA125 can be considered for a further three cycles of the same chemotherapy [V, B].

follow-up
History, physical examination including pelvic examination every 3 months for 2 years, every 4 months during the third year and every 6 months during years 4 and 5 or until progression is documented.

CA125 can accurately predict tumor relapse [I, A], and should be performed at each follow-up visit. CT scans should be performed if there is clinical or CA125 evidence for progressive disease.

recurrent disease
Patients with long intervals (>1 year) from primary surgery should be considered for surgical resection of recurrent disease [III, A]. Patients with long intervals (>6 months) from initial chemotherapy should be offered platinum-based combination chemotherapy (carboplatin + paclitaxel, carboplatin + gemcitabine) [I, A]. For patients with short treatment-free intervals and with second and later recurrences, palliative chemotherapy with pegylated liposomal doxorubicin, gemcitabine or topotecan should be considered [II, B].

note
Levels of evidence [I–V] and grades of recommendation [A–D] as used by the American Society of Clinical Oncology are given in square brackets. Statements without grading were
considered justified standard clinical practice by the expert authors and the ESMO faculty.

**Literature**